Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01265667 · ClinicalTrials.gov registry record · Phase 2
Trial of CF101 to Treat Patients With Psoriasis
A Phase 2 study, sponsored by Can-Fite BioPharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 293
- Enrollment target
NCT01265667: Completed Phase 2 study, sponsored by Can-Fite BioPharma.
NCT01265667 is a Phase 2 study that has completed, run by Can-Fite BioPharma. The registered enrollment target is 293 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (120% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01265667, a Phase 2 study, has completed, sponsored by Can-Fite BioPharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 293 participants
- Enrollment target
Study Summary
Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.
Primary Outcome
Achievement of PASI 75 indicates a 75% reduction in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)
Interventions
- DRUG Placebo
- DRUG CF101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 293 participants |
| Start Date | 2011-07 |
| Est. Completion | 2015-05 |
| Phase | Phase 2 |
What the finished NCT01265667 record still lists
NCT01265667 is an interventional study that assigns participants to a tested intervention. The registered 293 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (120% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01265667 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01265667 about?
NCT01265667 is a clinical study titled "Trial of CF101 to Treat Patients With Psoriasis". Eligible patients with Psoriasis will be treated with CF101 or placebo twice daily for 16 weeks. All subjects will receive open-lable CF101 in weeks 17-32.
What is the current status of trial NCT01265667?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 293 participants. The study started on 2011-07. Estimated completion is 2015-05.
What interventions are being tested in trial NCT01265667?
The interventions under investigation include: Placebo (DRUG), CF101 (DRUG).
Who is sponsoring clinical trial NCT01265667?
This trial is sponsored by Can-Fite BioPharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01265667's enrollment target sits among peer trials
293 191st of 2000 higher than 1,810 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05775159 · 294 participants · Phase 2
Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer
- NCT06262113 · 294 participants · NA
A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1
- NCT06338865 · 294 participants · NA
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
- NCT06395467 · 294 participants · NA
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia